CTOs on the Move

Interim HealthCare

www.interimhealthcare.com

 
Interim HealthCare Inc., founded in 1966, is a leading national franchisor of home care, hospice and healthcare staffing. It is part of Caring Brands International which also includes UK-based Bluebird Care and Australia-based Just Better Care, both well-known franchise brands in their countries. With more than 530 franchise locations in seven countries Caring Brands International is a global health care leader. Interim HealthCare in the United States is unique in combining the commitment of local ownership with the support of a national organization that develops innovative programs and quality standards that improve the delivery of service. Franchisees employ ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $500M-1 Billion

Executives

Name Title Contact Details

Similar Companies

PurposeCare

PurposeCare is an integrated platform company that coordinates care in the community with a focus on individuals who are dually eligible for Medicaid and Medicare.

MBK Associates

MBK Associates is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SW Carson Consulting Inc

SW Carson Consulting Inc is a Southlake, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

FHC Health Systems, Inc.

FHC Health Systems, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Relmada

Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.